The Role of Metabolomics in the Study of Kidney Diseases and in the Development of Diagnostic Tools

Biomarkers of Kidney Disease

Volumn , Issue , 2011, Pages 39-100

  Christians, Uwe ^a   Albuisson, Jeska ^a   Klawitter, Jost ^a   Klawitter, Jelena ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882439606     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-375672-5.10003-9     Document Type: Chapter

References (164)

1. Nicholson J.K., Lindon J.C. Metabonomics. Nature 2008, 455:1054-1056.
2. Neild G.H., Foxall PJD Lindon J.C., et al. Uroscopy in the 21st century: high-field NMR spectroscopy. Nephrol Dial Transplant 1997, 12:404-417.
3. Nicholson J.K., Lindon L.C., Holmes E. 'Metabonomics': understanding the metabolic response of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 11:1181-1189.
4. Holmes E., Wilson I.D., Nicholson J.K. Metabolic phenotyping in health and disease. Cell 2008, 134:714-717.
5. Nicholson J.K. Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2006, 2:52.
6. Biomarkers Definition Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
7. Wishart D.S. Metabolomics: the principles and potential applications to transplantation. Am J Transplant 2005, 5:2814-2820.
8. Rosner M.H. Urinary biomarkers for the detection of renal injury. Adv Clin Chem 2009, 49:73-97.
9. Christians U., Klawitter J., Bendrick-Peart J., et al. Toxicodynamic therapeutic drug monitoring of immunosuppressants: promises, reality and challenges. Ther Drug Monit 2008, 30:151-158.
10. Devarajan P. Emerging urinary biomarkers in the diagnosis of acute kidney injury. Expert Opin Med Diagn 2008, 2:387-398.
11. Schnackenberg L.K. Global metabolic profiling and its role in systems biology to advance personalized medicine in the 21st century. Expert Rev Mol Diagn 2007, 7:247-259.
12. Xu E.Y., Schaefer W.H., Xu Q. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways. Curr Opin Drug Discov Devel 2009, 12:40-52.
13. Nicholson J.K., Wilson I.D. Understanding global systems biology: metabonomics and the continuum of metabolism. Nature Rev Drug Discov 2003, 2:668-676.
14. Griffiths W.J., Wang Y. Mass spectrometry: from proteomics to metabolomics and lipidomics. Chem Soc Rev 2009, 38:1882-1896.
15. German J.B., Gillies L.A., Smilowitz J.T., et al. Lipidomics and lipid profiling in metabolomics. Curr Opin Lipidol 2007, 18:66-71.
16. Niemann C.U., Serkova N.J. Biochemical mechanisms of nephrotoxicity: application for metabolomics. Expert Opin Drug Metab Toxicol 2007, 3:527-544.
17. Burckhardt B.C., Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 2003, 146:95-158.
18. Coen M., Holmes E., Lindon J.C., et al. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol 2008, 21:9-27.
19. Oldiges M., Lütz S., Pflug S., et al. Metabolomics: current state and evolving methodologies and tools. Appl Microbiol Biotechnol 2007, 76:495-511.
20. Xia J., Bjorndahl T.C., Tang P., et al. MetaboMiner - semi-automated identification of metabolites from 2D NMR spectra of complex biofluids. BMC Bioinformatics 2008, 28:507.
21. Almstetter M.F., Appel I.J., Gruber M.A., et al. Integrative normalization and comparative analysis for metabolic fingerprinting by comprehensive two-dimensional gas chromatography-time-of-flight mass spectrometry. Anal Chem 2009, 81:5731-5739.
22. Nicholson J.K., Connelly J., Lindon J.C., et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002, 1:153-161.
23. Matsuda F., Shinbo Y., Oikawa A., et al. Assessment of metabolome annotation quality: a method for evaluating the false discovery rate of elemental composition searches. PLoS One 2009, 16:e7490.
24. Dettmer K., Aronov P.A., Hammock B.D. Mass spectrometry-based metabolomics. Mass Spectrom Rev 2007, 26:51-78.
25. Wishart D.S. Computational approaches to metabolomics. Methods Mol Biol 2010, 593:283-313.
26. Klawitter J., Haschke M., Kahle C., et al. Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose. Br J Clin Pharmacol April 14, 2010, [e-pub ahead of print].
27. Khoo S.H.G., Al-Rubeal M. Metabolomics as a complementary tool in cell culture. Biotechnol Appl Biochem 2007, 47:71-84.
28. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics techniques and applications to pharmaceutical research and development. Pharm Res 2006, 23:1075-1088.
29. Rifai N., Gillette M.A., Carr S.A. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006, 24:971-983.
30. Pasikanti K.K., Ho P.C., Chan E.C. Gas chromatography/mass spectrometry in metabolic profiling of biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2008, 871:202-211.
31. Slupsky C.M., Rankin K.N., Wagner J., et al. Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal Chem 2007, 79:6995-7004.
32. 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J Pharm Biomed Anal 2003, 33:1103-1115.
33. Lee J.W., Weiner R.S., Sailstad J.M., et al. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 2005, 22:499-511.
34. Issaq H.J., Van Q.N., Waybright T.J., et al. Analytical and statistical approaches to metabolomics research. J Sep Sci 2009, 32:2183-2199.
35. Dunn W.B., Bailey N.J., Johnson H.E. Measuring the metabolome: current analytical technologies. Analyst 2005, 130:606-625.
36. Drake S.K., Bowen R.A.R., Remaley A.T., et al. Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. Clin Chem 2004, 50:2398-2401.
37. Bowen R.A., Hortin G.L., Csako G., et al. Impact of blood collection devices on clinical chemistry assays. Clin Biochem 2010, 43:4-25.
38. Beckonert O., Keun H.C., Ebbels T.M.D., et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007, 2:2692-2703.
39. 31P topical magnetic resonance. Nature 1980, 287:736-738.
40. 31P NMR spectroscopy of rat organs, in situ, using chronically implanted radiofrequency coils. Proc Natl Acad Sci USA 1983, 80:7491-7495.
41. 1H nuclear magnetic resonance spectroscopy. Anal Biochem 2002, 304:220-230.
42. Lindon J.C., Holmes E., Bollard M.E., et al. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004, 9:1-31.
43. Reo N.V. NMR-based metabolomics. Drug Chem Toxicol 2002, 25:375-382.
44. Pan Z., Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal Bioanal Chem 2007, 387:525-527.
45. 1H-NMR-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int 2005, 67:1142-1151.
46. 1H NMR-based metabolic profiling studies. Anal Chem 2008, 80:3365-3371.
47. Gowda G.A., Zhang S., Gu H., et al. Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 2008, 8:617-633.
48. Schnackenberg K, Beger RD. Monitoring the health to disease continuum with global metabolic profiling and systems biology. Pharmacogenomics 2006, 7:1077-1086.
49. Shoemaker J.D., Elliot W.H. Automated screening of urine samples for carbohydrates, organic and amino acids after treatment with urease. J Chromatography B 1991, 562:125-128.
50. Pierce K.M., Hoggard J.C., Mohler R.E., et al. Recent advancements in comprehensive two-dimensional separations with chemometrics. J Chromatogr A 2008, 1184:341-352.
51. Adahchour M., Beens J., Brinkman U.A. Recent developments in the application of comprehensive two-dimensional gas chromatography. J Chromatogr A 2008, 1186:67-108.
52. Want E.J., O'Maille G., Smith C.A., et al. Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. Anal Chem 2006, 78:743-752.
53. Nordström A., Want E., Northen T., et al. Multiple ionization mass spectrometry strategy used to reveal the complexity of metabolomics. Anal Chem 2008, 80:421-429.
54. Annesley T.M. Ion suppression in mass spectrometry. Clin Chem 2007, 49:1041-1044.
55. Want E.J., Nordström A., Morita H., et al. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J Proteome Res 2007, 6:459-468.
56. Boernsen K.O., Gatzek S., Imbert G. Controlled protein precipitation in combination with chip-based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasma. Anal Chem 2005, 77:7255-7264.
57. Van der Werf M.J., Overkamp K.M., Muilwijk B., et al. Microbial metabolomics: toward a platform with full metabolic coverage. Anal Biochem 2007, 370:17-25.
58. Deming S.N. Chemometrics: an overview. Clin Chem 1986, 32:1702-1706.
59. Beger R.D., Sun J., Schnackenberg L.K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol Appl Pharmacol 2010, 243:154-166.
60. Baumgartner W.A., Cohen K.B., Fox L.M., et al. Manual curation is not sufficient for annotation of genomic databases. Bioinformatics 2007, 23:i41-48.
61. Ganter B., Zidek N., Hewitt P.R., et al. Pathway analysis tools and toxicogenomics reference databases for risk assessment. Pharmacogenomics 2008, 9:35-54.
62. Wheelock C.E., Wheelock A.M., Kawashima S., et al. Systems biology approaches and pathway tools for investigating cardiovascular disease. Mol Biosyst 2009, 5:588-602.
63. Materi W., Wishart D.S. Computational systems biology in drug discovery and development: methods and applications. Drug Discov Today 2007, 12:295-303.
64. Leach S.M., Tipney H., Feng W., et al. Biomedical discovery acceleration, with applications to craniofacial development. PLoS Comput Biol 2009, 5:e1000215.
65. Wishart D.S., Knox C., Guo A.C., et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009, 37(Database issue):D603-D610.
66. Halket J.M., Przyborowska A., Stein S.E., et al. Deconvolution gas chromatography/mass spectrometry of urinary organic acids - potential for pattern recognition and automated identification of metabolic disorders. Rapid Commun Mass Spectrom 1999, 13:279-284.
67. Kind T., Scholz M., Fiehn O. How large is the metabolome? A critical analysis of data exchange practices in chemistry. PLoS One 2009, 4:e5440.
68. Wishart D.S. Introduction to cheminformatics. Curr Protoc Bioinformatics 2007, Chapter 14: Unit 14.1.
69. Wishart D.S. Current progress in computational metabolomics. Brief Bioinform 2007, 8:279-293.
70. Conti M., Moutereau S., Esmilaire L., et al. Should kidney tubular markers be adjusted for urine creatinine? The example of urinary cystatin C. Clin Chem Lab Med 2009, 47:1553-1556.
71. Schnackenberg L.K., Sun J., Espandiari P., et al. Metabonomics evaluations of age-related changes in urinary compositions of male Sprague-Dawley rats and effects of data normalization methods on statistical and quantitative analysis. BMC Bioinformatics 2007, 8(Suppl 7):S3.
72. 1H NMR metabonomics. Anal Chem 2006, 78:4281-4290.
73. Craig A., Cloarec O., Holmes E., et al. Scaling and normalization effects in NMR spectroscopic metabonomic data sets. Anal Chem 2006, 78:2262-2267.
74. 1H NMR spectra for metabolic profiling. Anal Chem 2009, 81:6080-6088.
75. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine. Guidance for the Industry. Bioanalytical Method Validation. Version May 2001. (accessed 4/1/2010). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/UCM070107.pdf.
76. Clinical Laboratory and Standard Institute. (accessed 4/1/2010). http://www.clsi.org.
77. European Agency for the Evaluation of Medicinal Products. ICH topic Q2B. Validation of analytical procedures: methodology. Note for guidance on analytical procedures: Methodology. CPMP ICH/281/95. Version November 6, 1996. (accessed 4/1/2010). http://www.ema.europa.eu/pdfs/human/ich/028195en.pdf.
78. Wagner J.A., Williams S.A., Webster C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther 2007, 81:104-107.
79. The Standard Metabolic Reporting Structures Working Group Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol 2005, 23:833-838.
80. Castle A.L., Fiehn O., Kaddurah-Daouk R., et al. Metabolomics standards workshop and the development of international standards for reporting metabolomics experimental results. Briefings Bioinformatics 2006, 7:159-162.
81. Morrison N., Cochrane G., Faruque N., et al. Concept of sample in OMICS technology. OMICS 2006, 10:127-137.
82. 1H NMR-based metabonomic urinalysis. Chem Res Toxicol 2002, 15:1380-1386.
83. 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP study. Anal Chem 2006, 78:2199-2208.
84. Burckart G.J., Amur S., Goodsaid F.M., et al. Qualification of biomarkers for drug development in organ transplantation. Am J Transplant 2008, 8:267-270.
85. Müller P.Y., Dieterle F. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring. Expert Opin Drug Metab Toxicol 2009, 5:1023-1038.
86. Lesko L.J., Atkinson A.J.Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001, 41:347-366.
87. Fawcett T. Introduction to ROC analysis. Pattern Recogn Lett 2006, 27:861-874.
88. Goodsaid F.M., Frueh F.W., Mattes W. Strategic paths for biomarker qualification. Toxicology 2008, 245:219-223.
89. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Version May 1998. (accessed 1/18/2010). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati on/Guidances/ucm078749.pdf.
90. Goodsaid F., Frueh F. Process map proposal for the validation of genomic biomarkers. Pharmacogenomics 2006, 7:773-782.
91. Berl T. American Society of Nephrology Renal Research Report. J Am Soc Nephrol 2005, 16:1886-1903.
92. Beger R.D., Holland R.D., Sun J., et al. Metabonomics of acute kidney injury in children after cardiac surgery. Pediatr Nephrol 2008, 23:977-984.
93. Cascante M., Boros L.G., Comin-Anduix B., et al. Metabolic control analysis in drug discovery and disease. Nat Biotechnol 2002, 20:243-249.
94. Martin G., Chauvin M.F., Dugelay S., et al. Non-steady state model applicable to NMR studies for calculating flux rates in glycolysis, gluconeogenesis, and citric acid cycle. J Biol Chem 1994, 42:26034-26039.
95. 13C metabolic flux analysis. Metab Eng 2001, 3:265-283.
96. Vilasi A., Cutillas P.R., Maher A.D., et al. Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome. Am J Physiol Renal Physiol 2007, 293:F456-F467.
97. Taylor S.L., Gant S., Bukanov N.O., et al. A metabolomics approach using juvenile cystic mice to identify urinary biomarkers and altered pathways in polycystic kidney disease. Am J Physiol Renal Physiol 2010, 298:F909-F922.
98. Wishart D.S. Application of metabolomics in drug discovery and development. Drugs R and D 2008, 9:307-322.
99. Shockcor J.P., Holmes E. Metabonomic applications in toxicity screening and disease diagnostics. Curr Topics Med Cem 2002, 2:35-51.
100. Ebbels T.M., Keun H.C., Beckonert O.P., et al. Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J Proteome Res 2007, 6:4407-4422.
101. Boudnock K.J., Mitchell M.W., Nemet L., et al. Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicol Pathol 2009, 37:280-292.
102. Gartland K.P.R., Bonner F.W., Nicholson J.K. Investigations into the biochemical effects of region-specific nehprotoxins. Mol Pharmacol 1989, 35:242-250.
103. 1H-NMR spectra of urine using an artificial neural network. J Pharm Biomed Anal 1995, 13:205-211.
104. Anthony M.L., Sweatman B.C., Beddell C.R., et al. Pattern recognition classification of the site of nephrotoxicity based in metabolic data derived from proton nuclear magnetic resonance spectra of urine. Mol Pharmacol 1994, 48:199-211.
105. 1H NMR spectroscopy of urine combined with pattern recognition. NMR Biomed 1998, 11:235-244.
106. Williams R.E., Major H., Lock E.A., et al. D-serine nephrotoxicity: a HPLC-TOF/MS-based metabonomics approach. Toxicology 2005, 207:179-209.
107. Sieber M., Hoffmann D., Adler M., et al. Comparative analysis of novel noninvasive renal biomarkers and metabonomic changes in a rat model of gentamycin nephrotoxicity. Toxicol Sci 2009, 109:336-349.
108. Holmes E., Bonner F.W., Sweatman B.C., et al. Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury(II) chloride and 2-bromoethanamine. Mol Pharmacol 1992, 42:922-930.
109. 1H-NMR and HPLC-TOF/MS: time dependent changes in the urinary profile of endogenous metabolites as a result of nephrotoxicity. Analyst 2004, 129:535-541.
110. Nicholson J.K., Timbrell J.A., Sadler P.J. Proton NMR spectra of urine as indicators of renal damage. Mercury-induced nephrotoxicity in rats. Mol Pharmacol 1985, 27:644-651.
111. Anthony M.L., Gartland K.P., Beddell C.R., et al. Studies of the biochemical toxicology of uranyl nitrate in the rat. Arch Toxicol 1994, 68:43-53.
112. Klawitter J., Bendrick-Peart J., Rudolph B., et al. Urine metabolites reflect time-dependent effects of ciclosporin and sirolimus on rat kidney function. Chem Res Toxicol 2009, 22:118-128.
113. Sieber M., Wagner S., Rached E., et al. Metabonomic study of ochratoxin A toxicity in rats after repeat administration: phenotypic anchoring enhances the ability for biomarker discovery. Chem Res Toxicol 2009, 22:1221-1231.
114. Portilla D., Li S., Nagothu K.K., et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int 2006, 69:2194-2204.
115. 1H NMR spectroscopy, HPLC-TOF/MS and chemometrics. J Pharm Biomed Anal 2004, 35:599-608.
116. 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamycin-induced nephrotoxicity in the rat. Biomarkers 2005, 10:173-187.
117. 1H-NMR spectroscopy. J Toxicol Environ Health A 2009, 72:374-384.
118. 2H NMR spectroscopic studies on the metabolism and biochemical effects of 2-bromoethanamine in the rat. Biochem Pharmacol 1995, 49:1349-1359.
119. Womer K.L., Kaplan B. Recent developments in kidney transplantation - a critical assessment. Am J Transplant 2009, 9:1265-1271.
120. Chapman J.R., O'Connell P.J., Nankivell B.J. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005, 16:3015-3026.
121. Wishart D.S. Metabolomics: a complementary tool in renal transplantation. Contrib Nephrol 2008, 160:76-87.
122. Fuller T.F., Serkova N., Neimann C.U., et al. Influence of donor pretreatment with N-acetylcysteine on ischemia/reperfusion injury in rat kidney grafts. J Urol 2004, 171:1296-1300.
123. Hauet T., Gibelin H., Godart C., et al. Kidney retrieval conditions influence damage to renal medulla: evaluation by proton nuclear magnetic resonance (NMR) spectroscopy. Clin Chem Lab Med 2000, 38:1085-1092.
124. Hauet T., Baumert H., Gibelin H., et al. Noninvasive monitoring of citrate, acetate, lactate, and renal medullary osmolyte excretion in urine as biomarkers of exposure to ischemic reperfusion injury. Cryobiology 2000, 41:280-291.
125. Gibelin H., Eugene M., Hebrard W., et al. A new approach to the evaluation of liver graft function by nuclear magnetic resonance spectroscopy. A comparative study between Euro-Collins and University of Wisconsin solutions. Clin Chem Lab Med 2000, 38:1133-1136.
126. Hauet T., Baumert H., Gibelin H., et al. Citrate, acetate and renal medullary osmolyte excretion in urine as predictor of renal changes after cold ischaemia and transplantation. Clin Chem Lab Med 2000, 38:1093-1098.
127. Hauet T., Gibelin H., Richer J.P., et al. Influence of retrieval conditions on renal medulla injury: evaluation by proton NMR spectroscopy in an isolated perfused pig kidney model. J Surg Res 2000, 93:1-8.
128. Hauet T., Goujon J.M., Tallineau C., et al. Early evaluation of renal reperfusion injury after prolonged cold storage using proton nuclear magnetic resonance spectroscopy. Br J Surg 1999, 86:1401-1409.
129. Schmitz V., Klawitter J., Bendrick-Peart J., et al. Graft flushing with histidine-tryptophane-ketoglutarate (HTK) followed by extended cold preservation in University of Wisconsin (UW) solution in a rat kidney transplantation model - an improved preservation protocol?. Eur J Surg Res 2006, 38:388-398.
130. 1H-NMR-based metabolic signatures of mild and severe ischemia/reperfusion injury in rat kidney transplants. Kidney Int 2005, 67:1142-1157.
131. Domański L., Safranow K., Ostrowski M., et al. Oxypurine and purine nucleoside concentrations in renal vein of allograft are potential markers of energy status of renal tissue. Arch Med Res 2007, 38:240-246.
132. Ojo A.O. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007, 27:498-507.
133. Schmitz V., Klawitter J., Bendrick-Peart J., et al. Metabolic profiles in urine reflect nephrotoxicity of sirolimus and ciclosporin following rat kidney transplantation. Nephron 2009, 111:e80-e91.
134. Klawitter J., Kushner E., et al. Association of immunosuppressant-induced protein changes in the rat kidney with changes in urine metabolite patterns: a proteo-metabonomic study. J Proteome Res 2010, 9:865-875.
135. Stapenhorst L., Sassen L., Beck B., et al. Hypocitrateuria as a risk factor for nephrocalcinosis after kidney transplantation. Pediatr Nephrol 2005, 20:652-656.
136. Serkova N.J., Christians U. Biomarkers for toxicodynamic monitoring of immunosuppressants: NMR-based quantitative metabonomics of the blood. Ther Drug Monit 2005, 20:652-656.
137. Kanaby M., Akcay A., Huddam B., et al. Influence of ciclosporin and tacrolimus on serum uric acid levels in stable kidney transplant recipients. Transplant Proc 2005, 37:3119-3120.
138. Perico N., Codreanu I., Caruso M., et al. Hypoeruricemia in kidney transplantation. Contrib Nephrol 2005, 147:124-131.
139. Armstrong K.A., Johnson D.W., Campbell S.B., et al. Does uric acid have a pathogeneric role in graft dysfunction and hypertension in renal transplant patients?. Transplantation 2005, 80:1565-1571.
140. Foxall P.J., Mellotte G.J., Bending M.R., et al. NMR spectroscopy as a novel approach to the monitoring of renal transplant function. Kidney Int 1993, 43:234-245.
141. Le Moyec L., Pruna A., Eugène M., et al. Proton nuclear magnetic resonance spectroscopy of urine and plasma in renal transplantation follow-up. Nephron 1993, 65:433-439.
142. Knoflach A., Binswanger U. Serum hippuric acid concentration in renal allograft rejection, ureter obstruction, and tubular necrosis. Transpl Int 1994, 7:17-21.
143. Rush D., Somorjai R., Deslauriers R., et al. Subclinical rejection - a potential surrogate marker for chronic rejection - may be diagnosed by protocol biopsy or urine spectroscopy. Ann Transplant 2000, 5:44-49.
144. Wang N.J., Zhou Y., Zhu T.Y., et al. Prediction of acute cellular renal allograft rejection by urinary metabolomics using MALDI-FTMS. J Proteome Res 2008, 7:3597-3601.
145. Rush D. Can protocol biopsy better inform our choices in renal transplantation?. Transplant Proc 2009, 41(6 Suppl):S6-S8.
146. Serkova N.J., Spratlin J.L., Eckhardt S.G. NMR-based metabolomics: translational application and treatment of cancer. Curr Opin Mol Ther 2007, 9:572-585.
147. Kim K., Aronov P., Zakharin S.O., et al. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009, 83:558-570.
148. Kind T., Tolstikov V., Fiehn O., et al. A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 2007, 363:185-195.
149. 1H NMR spectroscopy of intact liver and kidney: optimization of sample preparation procedures and biochemical stability of tissue during spectral acquisition. Anal Biochem 2000, 282:16-23.
150. 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 1998, 17:125-132.
151. 1H magic-angle spinning (MAS) NMR spectra. NMR Biomed 2000, 13:64-71.
152. Righi V., Mucci A., Schenetti L., et al. Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues. Anticancer Res 2007, 27:3195-3204.
153. Chung Y.L., Griffith J.R. Using metabolomics to monitor anticancer drugs. Ernst Schering Found Symp Proc 2008, 4:55-78.
154. Legido-Quigley C., Stella C., Perez-Jiminez F., et al. Liquid-chromatography-mass spectrometry methods for urinary biomarker detection in metabonomic studies with application to nutritional studies. Biomed Chromatogr 2010, 24(7):737-743. Nov 11, 2009 (epub ahead of print).
155. Foxall P.J.D., Bewley S., Neild G., et al. Analysis of fetal and neonatal urine using proton nuclear magnetic resonance spectroscopy. Arch Dis Child 1995, 73:F153-F157.
156. 1H-NMR metabolic profiling of human neonatal urine. Magn Reson Mater Phy 2006, 19:305-312.
157. Waters N.J., Waterfield C.J., Farrant R.D., et al. Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. Chem Res Toxicol 2005, 18:639-654.
158. Waters N.J., Holmes E., Williams A., et al. NMR and pattern recognition studies on the time-related metabolic effects of alpha-naphthylisothiocyanate on liver, urine, and plasma in the rat: an integrative metabonomic approach. Chem Res Toxicol 2001, 14:1401-1412.
159. Ishihara K., Katsutani N., Asai N., et al. Identification of urinary biomarkers useful for distinguishing a difference in mechanism of toxicity in rat models of cholestasis. Basic Clin Pharmacol Toxicol 2009, 105:156-166.
160. Baker M. In biomarkers we trust?. Nat Biotechnol 2005, 23:297-304.
161. Billelo J.A. The agony and ecstasy of 'omic' technologies in drug development. Curr Mol Med 2005, 5:39-52.
162. Miller M.G. Environmental metabolomics: a SWOT analysis (strengths, weaknesses, opportunities and threats). J Proteome Res 2007, 6:540-545.
163. Heijne W.H., Kienhuis A.S., van Ommen B., et al. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev Proteomics 2005, 2:767-780.
164. Koop R. Combinatorial biomarkers: from early toxicology assays to patient population profiling. Drug Discov Today 2005, 10:781-788.